Article
Gastroenterology & Hepatology
Kimberly P. Newton, Laura A. Wilson, Nancy A. Crimmins, Mark H. Fishbein, Jean P. Molleston, Stavra A. Xanthakos, Cynthia Behling, Jeffrey B. Schwimmer
Summary: The study aimed to determine the incidence of type 2 diabetes (T2D) in children with nonalcoholic fatty liver disease (NAFLD) and identify associated risk factors. The results showed a high incidence rate of T2D in children with NAFLD, and being female, having a higher BMI z-score, and more severe liver histology were independent risk factors for T2D development.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Seoil Moon, Goh Eun Chung, Sae Kyung Joo, Jeong Hwan Park, Mee Soo Chang, Ji Won Yoon, Bo Kyung Koo, Won Kim
Summary: The PNPLA3 rs738409 genotype is associated with the risk of diabetes mellitus (DM), but this association differs between individuals with and without nonalcoholic fatty liver disease (NAFLD).
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Gastroenterology & Hepatology
Xinrong Zhang, Grace Lai-Hung Wong, Terry Cheuk-Fung Yip, Johnny T. K. Cheung, Yee-Kit Tse, Vicki Wing-Ki Hui, Huapeng Lin, Jimmy Che-To Lai, Henry Lik-Yuen Chan, Alice Pik-Shan Kong, Vincent Wai-Sun Wong
Summary: The duration of T2D is not associated with the occurrence of liver-related events, while age is. Therefore, screening for liver disease in patients with NAFLD and T2D starting at the age of 50 is reasonable.
Article
Multidisciplinary Sciences
Samit Ghosal, Debasis Datta, Binayak Sinha
Summary: GLP1-RA treatment shows significant improvement in liver function, weight reduction, decrease in liver fat content, better glycemic control, and reduction in hepatic inflammation for patients with both T2D and NAFLD.
SCIENTIFIC REPORTS
(2021)
Article
Endocrinology & Metabolism
Sami Qadri, Noora Ahlholm, Ida Lonsmann, Paola Pellegrini, Anni Poikola, Panu K. Luukkonen, Kimmo Porthan, Anne Juuti, Henna Sammalkorpi, Anne K. Penttila, Roberta D'Ambrosio, Giorgio Soardo, Diana J. Leeming, Morten Karsdal, Johanna Arola, Stergios Kechagias, Serena Pelusi, Mattias Ekstedt, Luca Valenti, Hannes Hagstrom, Hannele Yki-Jarvinen
Summary: This study investigated the impact of obesity on the performance of liver fibrosis biomarkers in NAFLD and found that ADAPT and FIB-4 are the best-performing biomarkers in obese patients, unaffected by body mass index.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Article
Gastroenterology & Hepatology
Daniel Q. Huang, Laura A. Wilson, Cynthia Behling, David E. Kleiner, Kris Kowdley, Srinivasan Dasarathy, Maral Amangurbanova, Norah A. Terrault, Anna Mae Diehl, Naga Chalasani, Brent A. Neuschwander-Tetri, Arun J. Sanyal, James Tonascia, NASH Clinical Res Network, Rohit Loomba
Summary: Limited data exist on fibrosis progression in biopsy-proven nonalcoholic fatty liver disease (NAFLD) in people with type 2 diabetes mellitus (T2DM). A multicenter study found that participants with T2DM had a significantly higher cumulative incidence of fibrosis progression compared to participants without T2DM. These findings have important implications for clinical practice and trial design.
Article
Endocrinology & Metabolism
Stergios A. Polyzos, Ilias D. Vachliotis, Christos S. Mantzoros
Summary: Nonalcoholic fatty liver disease (NAFLD), sarcopenia, and sarcopenic obesity (SO) are prevalent conditions, especially in the aging population, and there is no approved pharmacologic treatment for all of them. There are various mechanisms linking NAFLD with sarcopenia/SO, including alterations in adipokines, cytokines, hepatokines, and myokines. Observational studies support the association between NAFLD and sarcopenia/SO, with some cohort studies showing higher mortality in patients with both conditions. Treatment considerations for NAFLD and sarcopenia/SO are discussed, with limited evidence suggesting the potential benefits of pioglitazone or vitamin E.
METABOLISM-CLINICAL AND EXPERIMENTAL
(2023)
Review
Endocrinology & Metabolism
Jeanne M. M. Clark, Donna R. H. Cryer, Michelle Morton, Jay H. H. Shubrook
Summary: Nonalcoholic fatty liver disease (NAFLD) affects a large portion of the US population, with a significant number of patients progressing to nonalcoholic steatohepatitis (NASH) which increases the risk of liver-related complications and mortality. NASH is also associated with other metabolic comorbidities, adverse cardiovascular outcomes, and extrahepatic cancers. Early diagnosis of NAFLD is crucial in preventing progression to NASH, but it is often underdiagnosed. This review focuses on the clinical impact of NASH and provides practical guidance on its diagnosis and management for primary care providers, using case studies to illustrate real-world scenarios encountered in the primary care setting.
DIABETES OBESITY & METABOLISM
(2023)
Article
Medicine, General & Internal
Marcin Kosmalski, Sylwia Ziolkowska, Piotr Czarny, Janusz Szemraj, Tadeusz Pietras
Summary: NAFLD and T2DM are closely related, with common risk factors and pathogenesis. Understanding the coexistence of NAFLD and T2DM can help prevent the occurrence of other diseases and improve quality of life.
JOURNAL OF CLINICAL MEDICINE
(2022)
Review
Endocrinology & Metabolism
Maria Irene Bellini, Irene Urciuoli, Giovanni Del Gaudio, Giorgia Polti, Giovanni Iannetti, Elena Gangitano, Eleonora Lori, Carla Lubrano, Vito Cantisani, Salvatore Sorrenti, Vito D'Andrea
Summary: Nonalcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease worldwide and is closely associated with insulin resistance and diabetes. Treatment for NAFLD depends on the severity of the disease, including abstinence from alcohol, dietary changes, and reduction of risk factors, as well as procedures like weight loss surgery to improve liver condition.
WORLD JOURNAL OF DIABETES
(2022)
Review
Biochemistry & Molecular Biology
Julia A. Golubeva, Anna F. Sheptulina, Anastasia Yu. Elkina, Ekaterina O. Liusina, Anton R. Kiselev, Oxana M. Drapkina
Summary: Non-alcoholic fatty liver disease (NAFLD) and arterial hypertension (AH) are common non-communicable diseases worldwide. They often coexist and are associated with each other regardless of the presence of other metabolic factors.
Review
Gastroenterology & Hepatology
Eunji Ko, Eileen L. Yoon, Dae Won Jun
Summary: Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide, with an estimated prevalence of 25%. NAFLD is a major cause of liver cirrhosis, hepatocellular carcinoma, and death. Cardiovascular disease risk also increases with NAFLD severity.
CLINICAL AND MOLECULAR HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Leonardo Vinicius Monteiro de Assis, Muenevver Demir, Henrik Oster
Summary: Circadian profiling improves the detection of target genes and characterization of pathways in mouse models of nonalcoholic steatohepatitis. Fatty livers show a 3-hour advance in metabolic and clock gene transcript rhythms. Circadian profiling reveals temporal changes in lipid, carbohydrate, and cholesterol metabolic transcripts.
CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Review
Gastroenterology & Hepatology
Elina En Li Cho, Chong Zhe Ang, Jingxuan Quek, Clarissa Elysia Fu, Lincoln Kai En Lim, Zane En Qi Heng, Darren Jun Hao Tan, Wen Hui Lim, Jie Ning Yong, Rebecca Zeng, Douglas Chee, Benjamin Nah, Cosmas Rinaldi Adithya Lesmana, Aung Hlaing Bwa, Khin Maung Win, Claire Faulkner, Majd B. Aboona, Mei Chin Lim, Nicholas Syn, Anand V. V. Kulkarni, Hiroyuki Suzuki, Hirokazu Takahashi, Nobuharu Tamaki, Karn Wijarnpreecha, Daniel Q. Q. Huang, Mark Muthiah, Cheng Han Ng, Rohit Loomba
Summary: Non-alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease, with type 2 diabetes mellitus (T2DM) as a major predictor. This study determined a high prevalence of NAFLD, non-alcoholic steatohepatitis (NASH), and fibrosis in people with T2DM.
Article
Gastroenterology & Hepatology
Jiafeng Xia, Wanru Guo, Ming Hu, Xiuyuan Jin, Sitong Zhang, Boqiang Liu, Hangyuan Qiu, Kaicen Wang, Aoxiang Zhuge, Shengjie Li, Zhongkang Ji, Lanjuan Li, Kaijin Xu
Summary: With the drive of the circadian clock and feeding behavior, the microbial community generates rhythmic oscillations that play a crucial role in maintaining metabolic homeostasis. A time-restricted feeding regimen has shown promise in improving metabolism and microbial rhythmicity, but the underlying relationship is not well understood.
Article
Gastroenterology & Hepatology
Henriette Kreimeyer, Matthias Buechter, Jan Best, Robert K. Gieseler, Antonios Katsounas, Jan-Peter Sowa, Guido Gerken, Ali Canbay, Paul Manka, Lars P. Bechmann
Summary: This study aimed to evaluate the impact of liver maximum function capacity test (LiMAx) and coagulation factors on the prognosis of patients with acute liver failure (ALF). The results showed that LiMAx and fibrinogen may be effective indicators for predicting the survival rate of patients with nonacetaminophen-induced ALF, and they could be useful tools to assist in the decision-making process for liver transplantation.
DIGESTIVE DISEASES
(2023)
Article
Medicine, General & Internal
Peter Lemmer, Paul Manka, Jan Best, Alisan Kahraman, Julia Kaelsch, Ramiro Vilchez-Vargas, Alexander Link, Hsin Chiang, Guido Gerken, Ali Canbay, Lars P. Bechmann, Svenja Sydor
Summary: Alcoholic liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD) are leading causes of chronic liver diseases worldwide. While clinically distinguished by alcohol consumption, NAFLD coexists with moderate alcohol consumption in a growing proportion of the population. Studies have shown that even moderate alcohol consumption has impacts on liver injury, lipid metabolism, and the composition of gut microbiota.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Biochemistry & Molecular Biology
Paul Manka, Svenja Sydor, Julia M. Schaenzer-Ocklenburg, Malte Brandenburg, Jan Best, Ramiro Vilchez-Vargas, Alexander Link, Dominik Heider, Susanne Brodesser, Anja Figge, Andreas Jaehnert, Jason D. Coombes, Francisco Javier Cubero, Alisan Kahraman, Moon-Sung Kim, Julia Kaelsch, Sonja Kinner, Klaas Nico Faber, Han Moshage, Guido Gerken, Wing-Kin Syn, Ali Canbay, Lars P. Bechmann
Summary: Even in CeD patients in clinical remission under a gluten-free diet, alterations in gut-liver axis, especially bile acid signaling, may contribute to steatotic liver injury.
Letter
Gastroenterology & Hepatology
John Romano, Thaer Abdelfattah, Paul P. Manka, Michael Fuchs, Wing-Kin Syn
CLINICAL AND EXPERIMENTAL GASTROENTEROLOGY
(2022)
Article
Biochemistry & Molecular Biology
Svenja Sydor, Christian Dandyk, Johannes Schwerdt, Paul Manka, Dirk Benndorf, Theresa Lehmann, Kay Schallert, Maximilian Wolf, Udo Reichl, Ali Canbay, Lars P. Bechmann, Robert Heyer
Summary: High-calorie diets can lead to liver diseases and disruptions in the gut microbiome. Analyzing medical parameters and fecal metaproteome can help identify biomarkers for diagnosing non-alcoholic fatty liver disease (NAFLD) and hepatocellular carcinoma (HCC). Machine learning algorithms achieved high accuracy in distinguishing between healthy controls, NASH, and HCC.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Catherine Leyh, Niklas Heucke, Clemens Schotten, Matthias Buechter, Lars P. Bechmann, Marc Wichert, Alexander Dechene, Ken Herrmann, Dominik Heider, Svenja Sydor, Peter Lemmer, Johannes M. Ludwig, Josef Pospiech, Jens Theysohn, Robert Damm, Christine March, Maciej Powerski, Maciej Pech, Mustafa Oezcueruemez, Jochen Weigt, Verena Keitel, Christian M. Lange, Hartmut Schmidt, Ali Canbay, Jan Best, Guido Gerken, Paul P. Manka
Summary: LiMAx (R) is a non-invasive test that has the potential to predict post-interventional hepatic decompensation after radioembolization (RE) for hepatocellular carcinoma (HCC). Patients with lower baseline LiMAx (R) values have a higher risk of hepatic decompensation after RE.
Article
Multidisciplinary Sciences
Zhongyang Lu, Yanchun Li, Ai-Jun Li, Wing-Kin Syn, Stephen A. Wank, Maria F. Lopes-Virella, Yan Huang
Summary: This study demonstrated for the first time that loss of GPR40 in LDLR-deficient mice exacerbated HFD-induced hyperlipidemia, hepatic steatosis, inflammation, and fibrosis potentially through a CD36-dependent mechanism, suggesting that GPR40 may play a beneficial role in hyperlipidemia-associated NASH in LDLR-deficient mice.
Article
Gastroenterology & Hepatology
Martina Broecker-Preuss, Farhad Arzideh, Jan Best, Ali Canbay, Mustafa oezcueruemez, Paul Manka
Summary: Current reference intervals for basic liver laboratory diagnosis rely on manufacturers' information, ignoring known age and sex dependencies. By comparing the age-dependent distribution of flagged and non-flagged laboratory findings between different reference limits, we found notable differences. We suggest further analysis of the diagnostic and economic effects of reference limits adapted to the population of interest for liver diagnostics.
ZEITSCHRIFT FUR GASTROENTEROLOGIE
(2023)
Biographical-Item
Gastroenterology & Hepatology
Ali E. Canbay, Jan Best, Paul Manka
ZEITSCHRIFT FUR GASTROENTEROLOGIE
(2022)
Editorial Material
Gastroenterology & Hepatology
Paul Manka
DIGESTIVE DISEASES AND SCIENCES
(2023)
Article
Gastroenterology & Hepatology
Paul Manka, Jason D. Coombes, Svenja Sydor, Marzena K. Swiderska-Syn, Jan Best, Karine Gauthier, Leo A. van Grunsven, Ye H. Oo, Cindy Wang, Anna M. Diehl, Georg S. Hoenes, Lars C. Moeller, Anja Figge, Rene J. Boosman, Klaas N. Faber, Andrea Tannapfel, Oliver Goetze, Patricia Aspichueta, Christian M. Lange, Ali Canbay, Wing-Kin Syn
Summary: Thyroid hormones play a crucial role in hepatic fibrogenesis by regulating the phenotype of hepatic stellate cells (HSC) via the TGF beta signaling pathway. In vitro experiments showed that T3 can inhibit the expression of fibrogenic genes and promote wound healing in HSC. In vivo experiments on TR alpha-deficient mice further confirmed the importance of the TH-TR axis in liver fibrosis.
LIVER INTERNATIONAL
(2023)
Meeting Abstract
Gastroenterology & Hepatology
Henriette Kreimeyer, Svenja Sydor, Lara Kaiser, Cagatay Toskal, Anja Figge, Jan Best, Josef Pospiech, Oliver Goetze, Jan-Peter Sowa, Mustafa Oezcueruemez, Ali Canbay, Lars Bechmann, Paul Manka
JOURNAL OF HEPATOLOGY
(2023)
Article
Urology & Nephrology
Jacob Nysather, Eda Kaya, Paul Manka, Prakash Gudsoorkar, Wing-Kin Syn
Summary: Nonalcoholic fatty liver disease and chronic kidney disease share pathophysiological mechanisms and treatment strategies.
ADVANCES IN KIDNEY DISEASE AND HEALTH
(2023)
Meeting Abstract
Gastroenterology & Hepatology
Svenja Sydor, Ender Engin, Mustafa Oezcueruemez, Anja Figge, Josef Pospiech, Andreas Jaehnert, Jan Best, Wing-Kin Syn, Ali Canbay, Lars Bechmann, Paul Manka
JOURNAL OF HEPATOLOGY
(2022)
Meeting Abstract
Gastroenterology & Hepatology
Catherine Leyh, Niklas Heucke, Clemens Schotten, Matthias Buechter, Lars Bechmann, Marc Wichert, Alexander Dechene, Ken Hermann, Antonios Katsounas, Mustafa Ozcurumez, Dominik Heider, Svenja Sydor, Johannes M. Ludwig, Jens Theysohn, Robert Damm, Maciej Powerski, Maciej Pech, Ali Canbay, Jochen Weigt, Verena Keitel-Anselmino, Christian Lange, Jan Best, Paul Manka
JOURNAL OF HEPATOLOGY
(2022)